Overexpression and gene amplification of Cyclin D1 are frequent and contribute to dedifferentiation and cellular proliferative activity of intrahepatic cholangiocarcinoma
(1),
and overexpression also indicates a very poor prognosis for patients with
ICC. Cyclin D1 gene amplification has been reported in 30-50% of esophageal carcinosarcoma
(2)
and are believed to play an important role in malignant transformation processes.
Overexpression of Cyclin D1 is a key abnormality in lung carcinogenesis
(3)
and may have diagnostic and prognostic importance in the treatment of resectable
NSCLC. The gene has been observed to be amplified in carcinomas of the breast
(4)
and head and neck (5),
and translocated in parathyroid adenomas and centrocytic lymphomas
(6)
and has been associated with shortened survival time.
Methodology:
Minor groove binder (MGB) with Polymerase Chain Reaction (PCR) has been utilized to develop a quantitative, Real Time PCR based assay for the ultrasensitive detection and quantitation of Cyclin D1 gene amplification
(7).
References:
1) Sugimachi K., Aishima S., Taguchi K. et al (2001) J. Hepatol. 35 (1), 74.
2) Suzuki H., Fujioka Y., Nagashima K. (1998) Diagn. Mol. Pathol. 7 (5), 253.
3) Reissmann P.T., Koga H., Figlin R.A. et al (1999) J. Cancer Res. Clin. Oncol. 125 (2), 61.
4) Naidu R., Wahab N.A., Yadav M.M. et al (2002) Oncol. Rep. 9 (2), 409.
5) Davidson B.J., Lydiatt W.M., Abate M.P. et al (1996) Head Neck 18 (6), 512.
6) Swerdlow S.H., Yang W.I., Zukerberg L.R. et al (1995) Hum. Pathol. 26 (9), 999.
7) Glackner S., Lehmann U., Wilke N. et al (2000) Pathobiology 68 (4-5), 173.
Top |
